Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Increased to Strong-Buy at StockNews.com

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday.

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Trading Down 1.0 %

AUPH stock traded down $0.08 during midday trading on Thursday, hitting $8.34. The stock had a trading volume of 1,380,463 shares, compared to its average volume of 1,517,613. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.19 billion, a P/E ratio of -55.60 and a beta of 1.24. The business has a fifty day moving average price of $8.71 and a two-hundred day moving average price of $7.19. Aurinia Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $10.67.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $8.43, for a total value of $38,415.51. Following the transaction, the director now owns 13,356 shares in the company, valued at approximately $112,591.08. This represents a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of institutional investors have recently modified their holdings of AUPH. CWM LLC grew its position in Aurinia Pharmaceuticals by 247.7% in the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 8,180 shares during the period. FMR LLC lifted its stake in shares of Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 3,919 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the second quarter valued at about $84,000. China Universal Asset Management Co. Ltd. increased its position in shares of Aurinia Pharmaceuticals by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 10,700 shares in the last quarter. Finally, PFG Investments LLC raised its holdings in shares of Aurinia Pharmaceuticals by 37.9% in the 2nd quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 7,900 shares during the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.